Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

MannKind Corporation (MNKD) News: Substantial Take Off, Zacks Score and More

Editor’s Note: Related tickers: MannKind Corporation (NASDAQ:MNKD), Peregrine Pharmaceuticals (NASDAQ:PPHM)

MannKind attracts huge call strategy (OptionMonster)
An enormous call trade tops today’s option activity in biopharmaceutical company MannKind Corporation (NASDAQ:MNKD) as takeover speculation rises. optionMONSTER systems show that a trader bought 29,864 January 5 calls for the ask price of $1.98 in volume below previous open interest of more than 111,000. Seconds later, he or she sold the same number of January 9 calls for the bid price of $0.83 against open interest of just 1,380 at that strike, clearly indicating new activity. This could be a new vertical spread that is looking for MannKind Corporation (NASDAQ:MNKD) to trade up to the $9 area. Or this could be a trader rolling short calls, buying back the contracts at the lower strike and selling new ones at the higher level, possibly in conjunction with long stock in a covered call strategy. (See our Education section)

MannKind Corporation (NASDAQ:MNKD)

1 Giant Leap for MannKind (Fool)
MannKind Corporation (NASDAQ:MNKD) took one giant leap over the past few days. Shares have soared more than 30% since last week, after the company reported results for the first quarter. Was the news that great? Not really. It wasn’t that there was bad news. Actually, nothing announced by MannKind Corporation (NASDAQ:MNKD) last week came as a big surprise. The financial results were about where most expected them to be. Clinical trials for Afrezza are still under way, so there wasn’t any significant development on that front. About the only real news to come regarding those trials was that the patient dropout rate was slightly higher than the original protocol. However, MannKind Corporation (NASDAQ:MNKD) overenrolled those studies, so there isn’t a problem to be concerned about.

MannKind Given Neutral Rating at Zacks (MNKD) (MideastTime)
Zacks reissued their neutral rating on shares of MannKind Corporation (NASDAQ:MNKD) in a research report released on Tuesday morning, Analyst Ratings reports. Zacks currently has a $4.75 price target on the stock. Zacks’ analyst wrote, “MannKind’s first quarter 2013 net loss of $0.15 per share was narrower than the year-ago loss of $0.27 and the Zacks Consensus Estimate of a loss of $0.16. We expect investor focus to remain on Afrezza going forward. MannKind Corporation (NASDAQ:MNKD) expects to present results on Afrezza from 2 late-stage studies (Affinity 1 and Affinity 2) in mid-August this year.

Biotech Most Active & Overbought stocks… (CrazyJoys)
Shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) surged as much as 34 percent after the company signed an agreement with the Food and Drug Administration for Bavituximab for its late stage trial. …Shares of MannKind Corporation (NASDAQ:MNKD) have soared more than 30 percent since last week, after the company reported results for the first quarter. …MannKind Corporation (NASDAQ:MNKD) shares is closed at $ 5.19 in last trading session while trading in range of $ 5.19 – 5.43 with average volume 5.49 million shares. MNKD price to sales ratio in past twelve months was calculated as 38614.32 and price to cash ratio as 55.14. MannKind Corporation (NASDAQ:MNKD) return on assets ratio is recorded as -73.79%.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!